Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

Malcolm A. Smith, Christopher L. Morton, E. Anders Kolb, Richard Gorlick, Stephen T. Keir, Hernan Carol, Richard Lock, Min H. Kang, C. Patrick Reynolds, John M. Maris, Amy E. Watkins, Peter J. Houghton

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

Original languageEnglish (US)
Pages (from-to)307-310
Number of pages4
JournalPediatric Blood and Cancer
Volume54
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Pediatrics
Heterografts
TNF-Related Apoptosis-Inducing Ligand Receptors
Disease-Free Survival
Appointments and Schedules
Tumor Necrosis Factor-alpha
Immunoglobulin G
Monoclonal Antibodies
Apoptosis
Ligands
Cell Line
Growth
mapatumumab
Neoplasms
In Vitro Techniques
N-propyl-4-phenyl-1,2,3,6-tetrahydropyridine

Keywords

  • Developmental therapeutics
  • Mapatumumab
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Smith, M. A., Morton, C. L., Kolb, E. A., Gorlick, R., Keir, S. T., Carol, H., ... Houghton, P. J. (2010). Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 54(2), 307-310. https://doi.org/10.1002/pbc.22188

Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. / Smith, Malcolm A.; Morton, Christopher L.; Kolb, E. Anders; Gorlick, Richard; Keir, Stephen T.; Carol, Hernan; Lock, Richard; Kang, Min H.; Reynolds, C. Patrick; Maris, John M.; Watkins, Amy E.; Houghton, Peter J.

In: Pediatric Blood and Cancer, Vol. 54, No. 2, 02.2010, p. 307-310.

Research output: Contribution to journalArticle

Smith, MA, Morton, CL, Kolb, EA, Gorlick, R, Keir, ST, Carol, H, Lock, R, Kang, MH, Reynolds, CP, Maris, JM, Watkins, AE & Houghton, PJ 2010, 'Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 54, no. 2, pp. 307-310. https://doi.org/10.1002/pbc.22188
Smith, Malcolm A. ; Morton, Christopher L. ; Kolb, E. Anders ; Gorlick, Richard ; Keir, Stephen T. ; Carol, Hernan ; Lock, Richard ; Kang, Min H. ; Reynolds, C. Patrick ; Maris, John M. ; Watkins, Amy E. ; Houghton, Peter J. / Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2010 ; Vol. 54, No. 2. pp. 307-310.
@article{dd88188a660942b89d3fdb988aafc958,
title = "Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program",
abstract = "Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50{\%} growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.",
keywords = "Developmental therapeutics, Mapatumumab, Preclinical testing",
author = "Smith, {Malcolm A.} and Morton, {Christopher L.} and Kolb, {E. Anders} and Richard Gorlick and Keir, {Stephen T.} and Hernan Carol and Richard Lock and Kang, {Min H.} and Reynolds, {C. Patrick} and Maris, {John M.} and Watkins, {Amy E.} and Houghton, {Peter J.}",
year = "2010",
month = "2",
doi = "10.1002/pbc.22188",
language = "English (US)",
volume = "54",
pages = "307--310",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program

AU - Smith, Malcolm A.

AU - Morton, Christopher L.

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Keir, Stephen T.

AU - Carol, Hernan

AU - Lock, Richard

AU - Kang, Min H.

AU - Reynolds, C. Patrick

AU - Maris, John M.

AU - Watkins, Amy E.

AU - Houghton, Peter J.

PY - 2010/2

Y1 - 2010/2

N2 - Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

AB - Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that exclusively targets and activates tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). It was tested in vitro at concentrations from 0.01 to 100 μg/ml and in vivo at a dose of 10 mg/kg administered intraperitoneally using a twice-weekly schedule. Mapatumumab demonstrated limited activity against the 23 cell lines of the PPTP in vitro panel with no lines achieving 50% growth inhibition. Mapatumumab induced significant differences in event-free survival distribution compared to controls in 9 of 37 evaluable solid tumor xenografts tested, but in none of the 8 ALL xenografts.

KW - Developmental therapeutics

KW - Mapatumumab

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=74849125377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849125377&partnerID=8YFLogxK

U2 - 10.1002/pbc.22188

DO - 10.1002/pbc.22188

M3 - Article

VL - 54

SP - 307

EP - 310

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -